The preparation intended for Indonesia will be produced in India by the Serum Institute of India (SII).
Novavax has already submitted applications for permission to market its vaccine, incl. in Great Britain, Australia, India and the Philippines. According to President Stanley Erk, approval in these countries is a matter of “weeks, not months.”
The results of clinical trials related to the efficacy and safety of the vaccine are also regularly evaluated by the European Medicines Agency (EMA). As part of the joint vaccine procurement program, the European Union has ordered 100 million doses of Novavax, with an option to provide another 100 million doses.
Novavax is also evaluated by the World Health Organization (WHO). The approval of the World Health Organization will allow distribution of the preparation under the COVAX program, which aims to deliver vaccines to developing countries. Novavax and SII have committed to providing 1.1 billion doses of the COVAX vaccine. President Erk announced that the first deliveries of COVAX will be shipped later this year.
According to clinical trials, the Novavax vaccine contains approximately 90 percent. Efficacy in preventing coronavirus infection.
At the beginning of October, the Polish biotechnology company Mabion announced that it had concluded a contract worth 1.46 billion PLN with Novavax for the production of a vaccine against COVID-19. Serial production of the vaccine is scheduled to begin in Poland in December 2021. The contract was financially supported by the Polish Development Fund.
“Coffee enthusiast. Troublemaker. Incurable introvert. Subtly charming twitter scholar. Award-winning social mediaholic. Internet buff.”